Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
NCT04715191
Recruiting
Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CARE T cells, a new experimental treatment. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that pro... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
04/30/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma, Wilms Tumor, Yolk Sac Tumor
Register for Updates
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
NCT04789681
Recruiting
This phase II trial studies the effects of canakinumab in preventing lung cancer in patients who have high-risk pulmonary nodules. Canakinumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving canakinumab may prevent the development of lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Register for Updates
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
NCT04797767
Recruiting
This phase I/II trial finds the best dose, side effects and how well giving venetoclax in combination with cladribine, cytarabine, granulocyte colony-stimulating factor, and mitoxantrone (CLAG-M) in treating patients with acute myeloid leukemia and high-grade myeloid neoplasms. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as cladribine, cytarabine, and mitoxantrone, work in different ways to stop the growth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myeloid Neoplasm, Relapsed Acute Biphenotypic Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Mixed Phenotype Acute Leukemia, Relapsed Myeloid Neoplasm, Refractory Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myeloid Neoplasm, Recurrent Myeloid Sarcoma
Register for Updates
Wells and Enteric Disease Transmission
NCT04826991
Recruiting
Approximately 40 million people in the US are served by private, and frequently untreated, wells. Our best estimate is that 1.3 million cases of gastrointestinal illnesses (GI) per year are attributed to consuming water from untreated private wells in the US, but in reality, there are no robust epidemiological data that can be used to estimate cases of GI attributable to these sources. We propose the first randomized controlled trial (RCT) to estimate the burden of GI associated with private wel... Read More
Gender:
ALL
Ages:
Between 6 months and 59 months
Trial Updated:
04/30/2025
Locations: Temple University, Philadelphia, Pennsylvania
Conditions: Diarrhea, Gastrointestinal Infection, Respiratory Viral Infection, Waterborne Diseases
Register for Updates
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
NCT04929028
Recruiting
This phase II trial studies the side effects of chemotherapy and intensity modulated radiation therapy in treating patients with low-risk HIV-associated anal cancer, and nivolumab after standard of care chemotherapy and radiation therapy in treating patients with high-risk HIV-associated anal cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Zuckerberg San Francisco General Hospital, San Francisco, California +12 locations
Conditions: AIDS-Related Anal Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage III Anal Cancer AJCC v8, Anal Margin Squamous Cell Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Anal Non-Keratinizing Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8
Register for Updates
The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients
NCT05034432
Recruiting
To investigate the effect of VTA ablation at the time of LVAD implant to see if it can reduce the incidence of VTA after surgery
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: University of Rochester, Rochester, New York
Conditions: Arrythmia, Cardiomyopathies
Register for Updates
Pilot Study of Pancreatic Cancer Screening
NCT05058846
Recruiting
This study investigates how often abnormal findings from routine magnetic resonance imaging occur in people with genetic mutations in BReast CAncer gene. (BRCA), ataxia telangiectasia mutated gene (ATM), or PALB2 screened for pancreatic cancer. This study may lead to a greater understanding of cancer and potentially, improvements in cancer screening and treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: University of California San Francisco, San Francisco, California
Conditions: Pancreatic Carcinoma
Register for Updates
Autologous Dendritic Cell Vaccine in Kidney Cancer
NCT05127824
Recruiting
The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: UPMC Department of Urology, Pittsburgh, Pennsylvania
Conditions: Carcinoma, Renal Cell
Register for Updates
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
NCT05245227
Recruiting
To determine the effectiveness of using two medications simultaneously versus one medication, as is standard of care, in preventing early postpartum hemorrhage. There have been studies that looked at giving two medications and that there were reduced odds of postpartum hemorrhage. Specific Aim 1: Determine if double simultaneous uterotonic agent regimen (misoprostol and oxytocin) is superior to single agent (oxytocin only) in reducing postpartum hemorrhage. Specific Aim 2: Determine any poten... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Stony Brook University, Stony Brook, New York
Conditions: Postpartum Hemorrhage
Register for Updates
The Periviable GOALS Decision Support Tool
NCT05264779
Recruiting
The Periviable GOALS (Getting Optimal Alignment around Life Support) decision support tool (DST) is meant to facilitate informed shared decision-making regarding neonatal resuscitation for families facing the threat of a periviable delivery (deliveries occurring between 22 0/7 - 25 6/7 weeks gestational age). It is designed for parents to review independent of their clinician, and is intended to supplement, not replace, clinician counseling. The focus of the DST is the provision of patient-cente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: The University of California San Diego, San Diego, California +9 locations
Conditions: Pregnancy Preterm, Premature Birth, Pregnancy Complications, Obstetric Labor, Premature, Obstetric Labor Complications
Register for Updates
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
NCT05364086
Recruiting
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas +258 locations
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
NCT05395624
Recruiting
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/30/2025
Locations: UCSF, San Francisco, California +2 locations
Conditions: Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Register for Updates